Market Overview

Poxel Announces Completion of Patient Enrollment for TIMES 1 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan

  • Phase 3 TIMES 1 data readout is on track for the second quarter of
  • Japanese New Drug Application submission for Imeglimin targeted in
  • Diabetes is a fast-growing market in Asia and Japan is the second
    largest single market for type 2 diabetes outside of the U.S.; it is
    expected to grow to approximately $6 billion in 2020

(Euronext – POXEL - FR0012432516), a biopharmaceutical company
focused on the development of innovative treatments for metabolic
diseases, including type 2 diabetes and non-alcoholic steatohepatitis
(NASH), announced today that patient enrollment for the TIMES 1 trial in
the Phase 3 program for Imeglimin, an investigational therapeutic agent
for type 2 diabetes, in Japan has been completed. Referred to as TIMES (Trials
of IMeglimin for Efficacy and Safety),
the Imeglimin Phase 3 registration program in Japan includes three
pivotal trials to evaluate the efficacy and safety of Imeglimin in
approximately 1,100 patients. The TIMES 1 trial is a multicenter,
double-blind, placebo-controlled, randomized, monotherapy study in over
200 Japanese patients with type 2 diabetes.

"We continue to make progress advancing all three pivotal Phase 3 TIMES
trials for Imeglimin in Japan and completing patient enrollment of the
TIMES 1 trial is another important clinical milestone that takes us one
step closer to the Phase 3 data readout in 2019," said Thomas Kuhn, CEO
of Poxel. "Enrollment of the TIMES 2 and TIMES 3 trials is anticipated
to be completed during the second half of 2018. Our near-term focus in
Japan is the successful execution of TIMES, and, to this end, we are
working closely with our colleagues at Sumitomo Dainippon Pharma to
support the Japanese New Drug Application submission anticipated in

The TIMES program is a joint development effort between Poxel and
Sumitomo Dainippon Pharma. The companies entered into a strategic
partnership in October 2017 for the development and commercialization of
Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast
Asian countries.2

Imeglimin is an orally-available drug candidate with a novel mechanism
of action that has been observed in clinical studies to demonstrate
glucose lowering benefits by simultaneously targeting all three key
organs, which play an important role in the treatment of type 2
diabetes, the liver, muscles and the pancreas. Imeglimin has
demonstrated in preclinical studies the potential to address
mitochondrial dysfunction, which is believed to be at the core of type 2
diabetes pathophysiology. Imeglimin has completed Phase 1 and Phase 2
development in over 1,200 subjects in the U.S., Europe and Japan.

About the TIMES Program
TIMES (Trials of Imeglimin
for Efficacy and Safety), the Phase 3 program
for Imeglimin for the treatment of type 2 diabetes in Japan, consists of
three pivotal trials involving approximately 1,100 patients. The TIMES
program includes the following three trials that will be performed using
the dose of 1,000 mg twice daily:

TIMES 1: A Phase 3, 24-week, double-blind placebo-controlled,
randomized, monotherapy study to assess the efficacy, safety and
tolerability of Imeglimin in Japanese patients with type 2 diabetes,
using the change in HbA1c as the primary endpoint. Secondary endpoints
of the trial will include other standard glycemic and non-glycemic

TIMES 2: A Phase 3, 52-week, open-label, parallel-group study to assess
the long-term safety and efficacy of Imeglimin in Japanese patients with
type 2 diabetes. In this study, Imeglimin will be administrated orally
as a monotherapy or combination therapy with existing hypoglycemic
agents, including a DPP4 inhibitor, SGLT2 inhibitor, biguanide,
sulphonylurea and GLP1 receptor agonist.

TIMES 3: A Phase 3, 16-week, double-blind, placebo-controlled,
randomized study with a 36-week open-label extension period to evaluate
the efficacy and safety of Imeglimin in combination with insulin in
Japanese patients with type 2 diabetes and inadequate glycemic control
on insulin therapy.

About Imeglimin
Imeglimin is the first clinical candidate in
a new chemical class of oral agents called Glimins by the World Health
Organization. Imeglimin has a unique mechanism of action ("MOA") that
targets mitochondrial bioenergetics. Imeglimin acts on all three key
organs which play an important role in the treatment of type 2 diabetes:
the liver, muscles and the pancreas, and it has demonstrated glucose
lowering benefits by increasing insulin secretion in response to
glucose, improving insulin sensitivity and suppressing gluconeogenesis.
This MOA has the potential to prevent endothelial and diastolic
dysfunction, which can provide protective effects on micro- and
macro-vascular defects induced by diabetes. It also has the potential
for protective effect on beta-cell survival and function. This unique
MOA offers the potential opportunity for Imeglimin to be a candidate for
the treatment of type 2 diabetes in almost all stages of the current
anti-diabetic treatment paradigm, including monotherapy or as an add-on
to other glucose lowering therapies.

About Poxel SA
Poxel uses its development expertise in
metabolism to advance a pipeline of drug candidates focused on the
treatment of metabolic disorders, including type 2 diabetes and
non-alcoholic steatohepatitis (NASH). We have successfully completed the
Phase 2 clinical program for our first-in-class lead product, Imeglimin,
which targets mitochondrial dysfunction, in the U.S., Europe and Japan.
Together, with our partner Sumitomo Dainippon Pharma, we are conducting
the Phase 3 Trials of IMeglimin for Efficacy
and Safety (TIMES) program for the treatment of type 2
diabetes in Japan. Our partner Roivant Sciences
will be responsible for Imeglimin's development and commercialization in
countries outside of Poxel's partnership with Sumitomo Dainippon Pharma,
including the U.S. and Europe. Our second program, PXL770, a first in
class direct adenosine monophosphate-activated protein kinase (AMPK)
activator, is in Phase 1 and we plan on developing it for the treatment
of NASH. PXL770 could also have the potential to treat additional
metabolic diseases. We intend to generate further growth through
strategic partnerships and pipeline development. (Euronext: POXEL,

1Source: Oppenheimer & Co. estimates.
Indonesia, Vietnam, Thailand, Malaysia, The Philippines, Singapore,
Republic of the Union of Myanmar, Kingdom of Cambodia and Lao People's
Democratic Republic.

View Comments and Join the Discussion!